Abstract:One unexploited family of cancer biomarkers comprise glycoproteins, carbohydrates, and glycolipids (the Tumor Glycocode).A class of glycolipid cancer biomarkers, the tumor-marker gangliosides (TMGs) are presented here as potential diagnostics for detecting cancer, especially at early stages, as the biological function of TMGs makes them etiological. We propose that a quantitative matrix of the Cancer Biomarker Glycocode and artificial intelligence-driven algorithms will expand the menu of validated cancer biomarkers as a step to resolve some of the challenges in cancer diagnosis, and yield a combination that can identify a specific cancer, in a tissue-agnostic manner especially at early stages, to enable early intervention. Diagnosis is critical to reducing cancer mortality but many cancers lack efficient and effective diagnostic tests, especially for early stage disease. Ideal diagnostic biomarkers are etiological, samples are preferably obtained via non-invasive methods (e.g. liquid biopsy of blood or urine), and are quantitated using assays that yield high diagnostic sensitivity and specificity for efficient diagnosis, prognosis, or predicting response to therapy. Validated biomarkers with these features are rare. While the advent of proteomics and genomics has led to the identification of a multitude of proteins and nucleic acid sequences as cancer biomarkers, relatively few have been approved for clinical use. The use of multiplex arrays and artificial intelligence-driven algorithms offer the option of combining data of known biomarkers; however, for most, the sensitivity and the specificity are below acceptable criteria, and clinical validation has proven difficult. One strategic solution to this problem is to expand the biomarker families beyond those currently exploited. One unexploited family of cancer biomarkers comprise glycoproteins, carbohydrates, and glycolipids (the Tumor Glycocode). Here, we focus on a family of glycolipid cancer biomarkers, the tumor-marker gangliosides (TMGs). We discuss the diagnostic potential of TMGs for detecting cancer, especially at early stages. We include prior studies from the literature to summarize findings for ganglioside quantification, expression, detection, and biological function and its role in various cancers. We highlight the examples of TMGs exhibiting ideal properties of cancer diagnostic biomarkers, and the application of GD2 and GD3 for diagnosis of early stage cancers with high sensitivity and specificity. We propose that a quantitative matrix of the Cancer Biomarker Glycocode and artificial intelligence-driven algorithms will expand the menu of validated cancer biomarkers as a step to resolve some of the challenges in cancer diagnosis, and yield a combination that can identify a specific cancer, in a tissue-agnostic manner especially at early stages, to enable early intervention.

Capitalizing glycomic changes for improved biomarker-based cancer diagnostics

A serum glycomics approach to breast cancer biomarkers

Glycosylation in cancer as a source of biomarkers

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Altered glycosylation in cancer: molecular functions and therapeutic potential

Glycan-specific molecularly imprinted polymers towards cancer diagnostics: merits, applications, and future perspectives

The development of an integrated platform to identify breast cancer glycoproteome changes in human serum.

Glycosylation in cancer: mechanisms and clinical implications

Serum N-Glycome analysis reveals pancreatic cancer disease signatures

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides

Robust Glycoproteomics Platform Reveals a Tetra‐Antennary Site‐Specific Glycan Capping with Sialyl‐Lewis Antigen for Early Detection of Gastric Cancer

Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, Β1-4 Branching, Β1-6 Branching, and Α2-6 Sialylation in Cancer.

Primary breast cancer biomarkers based on glycosylation and extracellular vesicles detected from human serum

Molecularly Imprinted Polymers Outperform Lectin Counterparts and Enable More Precise Cancer Diagnosis.

Diagnostic Potential of Serum Glycome Analysis in Lung Cancer: A Glycopattern Study

Multiplexed surrogate analysis of glycotransferase activity in whole biospecimens

Invited - Glycoprotein (Glycan) Markers for the Early Detection of Breast Cancer

Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer

Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis

Mass Spectrometry-Based N-glycoproteomics for Cancer Biomarker Discovery.